×

CG Oncology’s immunotherapy reduces risk of tumor recurrence in bladder cancer trial

By Thomson Reuters Nov 16, 2026 | 8:08 AM

Nov 16 (Reuters) – CG Oncology said on Monday its experimental immunotherapy reduced the risk of tumor recurrence ​by 68% in certain patients with ‌a type of bladder cancer, meeting the main goal of a late-stage study.

Its shares jumped more than 30% to $98 in premarket ‌trading.

• ​The 367-patient trial was ⁠testing cretostimogene grenadenorepvec in ⁠patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) following complete tumor resection

• Cretostimogene was generally well tolerated, with safety results ​consistent with those reported in previous studies, the company said

• About 75% ⁠of newly diagnosed ⁠bladder cancers are NMIBC. Many ​people with NMIBC can be treated successfully, ​but the cancer can come back, and ‌some tumors can grow into the bladder muscle

• Cretostimogene is also being studied for BCG-unresponsive NMIBC, where the ⁠disease persists or recurs despite adequate treatment with Bacillus Calmette-Guerin

• The company now expects to ⁠submit its ‌application to the US ⁠Food and Drug Administration before ​the ‌end of March 2027 in ​order to ⁠incorporate additional data and a broader patient population

• CG Oncology will present more data at a conference in December

(Reporting by Sriparna Roy in Bengaluru; Editing by ​Shilpi Majumdar)